Landec/$LFCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Landec
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Ticker
$LFCR
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
524
ISIN
US5147661046
Website
Landec Metrics
BasicAdvanced
$303M
-
-$1.49
0.80
-
Price and volume
Market cap
$303M
Beta
0.8
52-week high
$8.63
52-week low
$3.68
Average daily volume
245K
Financial strength
Current ratio
2.706
Quick ratio
1.256
Long term debt to equity
264.507
Total debt to equity
274.83
Interest coverage (TTM)
-0.54%
Profitability
EBITDA (TTM)
-3.488
Gross margin (TTM)
33.45%
Net profit margin (TTM)
-34.27%
Operating margin (TTM)
-9.22%
Effective tax rate (TTM)
0.11%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-3.10%
Return on equity (TTM)
-83.58%
Valuation
Price to revenue (TTM)
2.086
Price to book
136.04
Price to tangible book (TTM)
-19.13
Price to free cash flow (TTM)
-25.017
Free cash flow yield (TTM)
-4.00%
Free cash flow per share (TTM)
-32.74%
Growth
Revenue change (TTM)
7.23%
Earnings per share change (TTM)
124.67%
3-year revenue growth (CAGR)
-1.19%
10-year revenue growth (CAGR)
-13.02%
3-year earnings per share growth (CAGR)
-11.91%
10-year earnings per share growth (CAGR)
11.33%
What the Analysts think about Landec
Analyst ratings (Buy, Hold, Sell) for Landec stock.
Bulls say / Bears say
Lifecore Biomedical's recent appointment of Mark DaFonseca as Chief Commercial Officer is expected to drive growth and expand the company's market presence. (Investing.com)
Analysts have initiated coverage of Lifecore Biomedical with a 'Buy' recommendation, indicating confidence in the company's future performance. (Nasdaq)
Lifecore Biomedical's stock has experienced a significant increase, with a 3.71% rise to $6.15, reflecting positive investor sentiment. (Investing.com)
Lifecore Biomedical's stock hit a 52-week low at $4.46, indicating potential challenges in the market. (Investing.com)
The company has undergone a strategic workforce reduction, terminating approximately 9% of its workforce, which may signal underlying operational challenges. (Investing.com)
Lifecore Biomedical is facing a securities class action investigation, which could lead to legal and financial repercussions. (Stockhouse)
Data summarised monthly by Lightyear AI. Last updated on 25 Jun 2025.
Landec Financial Performance
Revenues and expenses
Landec Earnings Performance
Company profitability
Landec News
AllArticlesVideos
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Accesswire·2 weeks ago
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
GlobeNewsWire·3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Landec stock?
Landec (LFCR) has a market cap of $303M as of June 30, 2025.
What is the P/E ratio for Landec stock?
The price to earnings (P/E) ratio for Landec (LFCR) stock is 0 as of June 30, 2025.
Does Landec stock pay dividends?
No, Landec (LFCR) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Landec dividend payment date?
Landec (LFCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Landec?
Landec (LFCR) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.